Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD

AICAR Benefits

AICAR Benefits from Direct Peptides Netherlands

AICAR, short for 5-aminoimidazole-4-carboxamide ribonucleoside, is a naturally occurring substance that plays a significant role in energy balance and various metabolic pathways. It’s an allosteric activator of AMP-activated protein kinase (AMPK), a protein involved in cellular energy homeostasis. In the athletic world, AICA Ribonucleotide has been noted for its potential to improve athletic performance, although it’s considered a prohibited substance [1]. It’s also used widely in research due to its ability to modulate role of AMPK signalling especially surrounding the improvement of endurance and performance in sports.

The History of AICAR Netherlands

In the medical world, AICAR has been used to restrict ischemia or the tissues’ blood supply. In early studies in the 1980s, it played an important role in preserving the heart’s blood flow. AICAR has also shown promise when it comes to treating diabetes and glucose metabolism because of its capability of increasing the tissues’ metabolic ability, which it does by modifying the muscle’s composition.

How AICAR Works Netherlands

Netherlands Clinical studies have shown when AICAR triggers AMPK, it leads to the skeletal muscle cells up take in glucose. In the independent experiments conducted by the Salk Institute and Howard Hughes Medical Centre, mouse models given the AICAR peptide were able to run by an increase of 44% without needing to train. It’s not surprising that when athletes heard about this compound, they began to use it without fearing testing or regulation up until 2011 when the world anti doping agency decided to prohibit synthetic amp activated protein kinase for human use.

Check out AICAR peptides from Direct Peptides.

Potent Endurance Stacking with AICAR and GW-501516

AICAR and GW-501516 (also known as Cardarine) are often used together in research because they have complementary effects on energy metabolism and are considered a performance enhancing drug. AICA Ribonucleotide, in the role of AMPK activator, stimulates glucose uptake and fatty acid oxidation, while GW-501516 acts on the peroxisome proliferator-activated receptor delta (PPARδ) to increase endurance and metabolic rate [2]. This combination could potentially enhance physical performance and aid in weight loss, although it’s important to note that both substances are on the World Anti-Doping Agency’s prohibited list. Moreover, while these substances show promise in preclinical studies, their long-term safety and efficacy in humans are not fully established, and thus they are only available for research use.

Is it Safe for Female Test Subjects to Use AICAR and GW?

Given that both are not hormone compounds, it is believed that females can use the compounds without virilization effects. Using AICAR helps to attack fat stores as well as increase the body’s fatty acid metabolism so that exercise pays off in helping you lose weight.

Dosage of AICAR

The dosages for AICAR for research purposes can differ depending on the physique of the subject. It is important to research the recommended dosage of any peptide before utilising it in your research to optimise it’s beneficial effects.

AICAR Studies Netherlands

This peptide is known for its incredible effect on increasing endurance levels and burning fat. Many Netherlands studies show this peptide often researched on rodent subjects results showed the peptide to induce metabolic genes. It’s capable of improving one’s running endurance significantly. This peptide can do enhance endurance by transforming fast-twitch muscle fibres into becoming a fat-burning, more energy-efficient, slow-twitch fibres.

AICAR, a ribonucleoside, has shown the possibility of being a potential treatment of various forms of Leukaemia. Netherlands Studies have demonstrated that it can induce apoptosis, or programmed cell death, in chronic lymphocytic leukaemia (CLL) cells, providing an alternative therapeutic option for patients with impaired p53 function [3]. Moreover, AICAR has been found to suppress cell proliferation and enhance sensitivity of other leukaemia types to treatment, suggesting its possible role in targeted therapy.

Furthermore, the peptide has shown potential in the treatment and management of diabetes. Netherlands Studies suggest that long-term administration  can improve glucose tolerance and lipid profile, potentially helping to manage symptoms of type 2 diabetes [4]. Moreover, AICA Ribonucleotide peptide treatment has been found to increase insulin-stimulated glucose uptake and reduce hepatic glucose output, indicating its therapeutic potential for insulin resistance and blood glucose regulation


The products mentioned in this posts intended for research and medical purposes only, to be only used by trained professionals.


[1] https://pubmed.ncbi.nlm.nih.gov/ 34064363/

[2] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2706130/

[3] https://pubmed.ncbi.nlm.nih.gov/ 20664053/

[4] https://pubmed.ncbi.nlm.nih.gov/ 15793229/


DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Netherlands Direct Peptides website: https://netherlands.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.

Related Posts